|
|
|
|
Vol. 61, Issue 5, 1081-1088, May 2002
Department of Pharmacology and Toxicology, Karl-Franzens-Universität Graz, Graz, Austria
| |
Abstract |
|---|
|
|
|---|
L-Arginine, the substrate of nitric oxide synthase, is
known to exert favorable effects in the prevention and treatment of cardiovascular diseases. In several conditions, including
atherosclerosis and ischemia/reperfusion, where oxygen metabolites are
thought to mediate endothelial and myocardial injury,
L-arginine has protective effects. Here we studied the
mechanisms by which L-arginine protects against oxygen
radical-induced myocardial injury. Buffer-perfused rat hearts were
subjected to oxygen radicals generated by electrolysis or to
hypoxanthine and xanthine oxidase, which generates superoxide anions
(O

1 for the reaction of L-arginine with
O
| |
Introduction |
|---|
|
|
|---|
L-Arginine
is a semiessential amino acid with a terminal guanidinium group that
serves as natural substrate for the synthesis of nitric oxide (NO) by
different NO synthases (NOS) (Palmer et al., 1988
; Andrew and Mayer,
1999
). NO is a potent endothelium-dependent vasodilator involved in the
regulation of vascular function and blood pressure homeostasis (Moncada
et al., 1991
). L-Arginine is a vascular protectant that
alleviates endothelial injury or corrects endothelial dysfunction.
Dietary supplementation of cholesterol-fed animals with
L-arginine reduced the extent of atheromatous lesions and
restored endothelium-dependent arteriolar vasodilation (Cooke et al.,
1992
; Kuo et al., 1992
). In hypercholesterolemic humans, L-arginine supplementation improved agonist-stimulated
arterial dilatation and blood flow and normalized monocyte and platelet adhesiveness, all of which contribute to the initiation and progression of atherosclerosis (Creager et al., 1990
; Drexler et al., 1991
; Clarkson et al., 1996
). L-Arginine also alleviates
myocardial reperfusion injury (Weyrich et al., 1992
; Sato et al., 1995
;
Brunner et al., 1997
). Hence, it was suggested that
L-arginine may serve as cost-effective therapy in human
diseases associated with endothelial dysfunction (Velianou et al.,
1999
). However, detrimental effects of L-arginine have been
reported as well (Takeuchi et al., 1995
; Mori et al., 1998
; Kronon et
al., 1999
).
The mechanism by which L-arginine exerts its protective
effects is unclear. The abnormal endothelial functions in
hypercholesterolemia or congestive heart failure appear to be related
to a reduced ability of the endothelium to produce or release
biologically active NO (Lefer and Ma, 1993
; Katz et al., 1999
). This is
generally attributed to reduced biosynthesis of NO and/or to an
increased oxidative degradation of NO. In support,
L-arginine was shown to restore endothelial function in
hypercholesterolemic rabbits by increasing NO production and protecting
NO from inactivation by superoxide anions (O
). However, the intracellular concentration of
L-arginine is ~0.5 to 0.8 mM (Baydoun et al., 1990
)
[i.e., far above the Km for NOS (2-4
µM)], making it unlikely that additional
L-arginine will stimulate NO synthesis. In a
model of intestinal ischemia-reperfusion, in which O
), suggesting that besides serving as NO precursor, L-arginine may be an antioxidant by scavenging
oxygen-derived free radicals.
The aim of this study was to elucidate the mechanism by which
L-arginine protects against oxygen radical-mediated cardiac injury. We used three different approaches. First, rat hearts were
exposed to oxygen radicals generated by electrolysis or to O
), further demonstrated distinct antioxidative properties of L-arginine.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. Cypridina (Vargula) luciferin analog (CLA, 2-methyl-6-phenyl-3,7-dihydroimidazol[1,2-a]pyrazine-3-one) was purchased from Nanolight Technology (Pittsburgh, PA). TEMPONE-H and NG-monomethyl-L-arginine (L-NMMA) was obtained from Alexis Corporation (Lausen, Switzerland). Bovine erythrocyte superoxide dismutase (SOD), horse heart cytochrome c (type VI), diethylenetriaminepentaacetic acid (DTPA), glycine, methionine, urate, NG-nitro-L-arginine (L-NNA), L-NAME, N-bathocuproinedisulfonic acid, hypoxanthine, xanthine oxidase, and catalase (from bovine liver) were all purchased from Sigma-Aldrich (Vienna, Austria).
Animals and Heart Perfusion.
Male Sprague-Dawley rats
(270-360 g) were anesthetized with diethyl ether, heparinized (1000 U
kg
1, i.p.), the hearts excised, arrested in
ice-cold buffer and mounted for retrograde perfusion (Langendorff mode)
at 10 ml min
1 per gram of heart wet weight as
previously described (Brunner et al., 1997
). The perfusion medium was a
modified Krebs-Henseleit bicarbonate buffer of the following
composition: 118.4 mM NaCl, 25 mM NaHCO3, 4.7 mM
KCl, 1.2 mM KH2PO4, 1.25 mM
CaCl2 (2 H2O), 1.2 mM
MgCl2 (6 H2O), 10.1 mM
D-glucose (H2O). Cardiac parameters were monitored continuously and included the positive and negative first derivative of pressure over time
(+dP/dtmax,
dP/dtmax) obtained via a left ventricular fluid-filled latex balloon; measure of
contractility), coronary perfusion pressure measured at the aortic root
(measure of coronary function), and heart rate.
Generation of Oxygen Radicals by Electrolysis.
Electrolysis
was performed essentially as previously described (Jackson et al.,
1986
). Two platinum wire electrodes were attached to the bottom of the
bubble trap of the perfusion apparatus (Harvard Instruments/Hugo Sachs
Elektronik, March-Hugstetten, Germany), directly neighboring the aortic
cannula. The distance between anode and cathode was 7 mm, and they were
localized 3 cm above the heart. A constant 15 mA direct current
generated by a power supply was applied to the perfusion buffer in the
bubble trap (~4.5 ml) for 10 s. The applied current was
continuously monitored with an ampere meter. This setup enabled the
generation of oxygen radicals in the perfusion buffer at a very short
distance from the heart.
Generation of O

1). The two reactants
were added to the perfusion buffer and the heart was perfused for 10 min in recirculation mode (total volume ~50 ml). Catalase (100 U
ml
1) was included to prevent the accumulation
of H2O2 (Southworth et al.,
1998
).
Protection against Electrolysis-Generated Oxygen Radicals (for
Protocol, see Fig. 1A).
Hearts were
equilibrated to establish stable perfusion conditions (15 min) and
exposed to test compounds for 15 min by recirculating the perfusion
buffer together with the test compound, followed by electrolysis for
10 s, during which the heart was still exposed to the test
compound, and a final perfusion period of 15 min (in nonrecirculating
mode), during which the oxygen radicals and test compounds were
gradually washed out. The following compounds were used: SOD (50 U
ml
1), L-arginine, glycine,
aminoguanidine (each 1 mM), and L-NNA (200 µM). SOD was
previously used mostly at 100 to 200 U ml
1
(Wang and Zweier, 1996
). The concentration of L-arginine
was about 5 times higher than the plasma concentration in adult humans or experimental animals (~0.2 mM) (Wu and Morris, 1998
). Glycine and
aminoguanidine were used at the same concentration as
L-arginine to allow direct comparisons, and 100 to 200 µM
of L-NNA is known to fully antagonize NOS activity (Klatt
et al., 1994
). "Control" refers to the effects of electrolysis in
the absence of test compounds. The oxygen radical content of
electrolyzed buffer and cardiac functional parameters were monitored
over 15 min after the start of electrolysis.
|
Protection against O



1; 10 times
more than in the first protocol, as a precaution), L-arginine,
N-
-acetyl-L-arginine,
aminoguanidine, and glycine (each 1 mM). Control perfusions were
performed in the absence of test compounds. In additional experiments,
SOD (500 U ml
1) that had been inactivated as
described previously (Hodgson and Fridovich, 1975
), and the
peroxynitrite scavengers methionine (1 mM) and urate (400 µM) were
used (Hooper et al., 1998
).
Determination of Electrolysis-Generated Oxygen Radical Scavenging
by CLA Assay.
Oxygen radicals generated by electrolysis were
quantified using CLA-enhanced chemiluminescence as previously described
(Skatchkov et al., 1998
). Briefly, 45 s after the start of
electrolysis ~120 µl of the perfusion buffer were collected from
the aortic cannula (i.e., in absence of a heart), 100 µl of it were
added to 10 µl of CLA solution (final concentration, 50 µM in 50 mM
Tris buffer, containing 1 mM MgCl2, 100 µM
DTPA, and 50 µM N-bathocuproinedisulfonic acid), mixed and
placed into a liquid scintillation vial. Chemiluminescence was counted
for 30 s in a liquid scintillation counter. The chemiluminescence measured in an aliquot of perfusion buffer before electrolysis was
defined as background signal and subtracted. All measurements were
performed within 15 s after sample collection.
Determination of O
1
xanthine oxidase in PBS (10 mM, pH 7.4) at 25°C. Detection of O
). The reduction of cytochrome c in the absence and
presence of L- or
D-arginine, derivatives of
L-arginine (L-NNA,
L-NAME, L-NMMA),
N-
-acetyl-L-arginine, glycine, and
aminoguanidine (concentration range 100 nM to 10 mM) were recorded for
5 min against blank samples containing 50 U ml
1
SOD. The rates were calculated by linear regression. The inhibition of
cytochrome c reduction by test compounds is expressed as
percentage of the rate obtained in the absence of test drug (=100%).
Determination of O

). The assay mixture consisted of 1 mM
hypoxanthine, 5 mU ml
1 xanthine oxidase, 30 µM TEMPONE-H (10 mM in PBS) and 100 µM of the transition metal
chelator DTPA in 10 mM PBS, pH 7.4. L-Arginine, glycine,
aminoguanidine, and the combination of glycine and aminoguanidine in
the concentration range of 100 nM to 10 mM were tested. Samples were
placed in 50-µl micropipettes (Brand, Wertheim, Germany) and EPR
spectra were recorded at room temperature using a MiniScope MS 100 EPR
spectrometer (Magnettech, Berlin, Germany). The instrument settings
were as follows: center field 3370 G, sweep width 100 G, sweep time 50 G, modulation amplitude 1.5 G, power attenuation 7 dB, receiver gain
9 × 102. Spectra were recorded in 1-min
intervals for 5 min. The intensity of each spectrum (amplitude) was
determined, and the rate of the increase in the intensity calculated by
linear regression. Inhibition of the rate by the test compounds is
expressed as percentage of the rate obtained in the absence of test
compound (=100%).
Rate Constant for the Reaction of O


1) in the presence of TEMPONE-H (30 µM) as
spin trap and varying concentrations of L-arginine (between
0.1 and 10,000 µM). Rates of TEMPONE formation were determined by EPR
and plotted against the different L-arginine
concentrations. The EC50 value of
L-arginine was calculated using the Hill equation. Assuming
that L-arginine solely competes with TEMPONE-H in the
reaction with O



1) (Dikalov et al., 1997
), the apparent rate
constant for L-arginine is given by
kapp = [TEMPONE-H]/[EC50 of
L-arginine] × k (TEMPONE-H with
O
Statistical Analysis. Data are presented as arithmetic mean ± S.E.M. Differences were analyzed for statistical significance using Student's t test. EC50 values were computed by the Hill equation, asterisk indicates statistical significance at P < 0.05.
| |
Results |
|---|
|
|
|---|
Protective Effects of L-Arginine against Myocardial
Injury Induced by Oxygen Radicals.
First, we studied the cardiac
effects of oxygen radicals that were generated by electrolysis of the
perfusion buffer. Figure 1A shows the experimental protocol and Fig. 1B
shows the amounts of oxygen radicals (reactive oxygen intermediates,
ROI) generated. Immediately after electrolysis, there was a burst of
free radicals that prompted a strong signal at 1 min in the CLA-based
chemiluminescence assay, followed by quick decomposition and washout of
radicals within 3 min. Between 3 and 15 min, the oxygen radical level
was less than 5% of the initial amounts (Fig. 1B). The functional effects of electrolysis are shown in Fig. 1C. Before electrolysis, +dP/dtmax was 2626 ± 126 mm Hg
s
1, and coronary perfusion pressure was 50 ± 2 mm Hg (n = 7). Electrolysis (15 mA, 10 s) of
the perfusion medium resulted in an immediate decline in left
ventricular +dP/dtmax, with a minimum of
1471 ± 136 mm Hg s
1 after 3 min (56% of
baseline), followed by gradual recovery to 1934 ± 113 mm Hg
s
1 (74% of baseline) at 15 min
(P < 0.05 versus baseline; circles in Fig. 1C).
Coronary perfusion pressure increased to 110 ± 4 mm Hg after 3 min (2.2-fold), indicating endothelial dysfunction, and partially
recovered after 15 min (67 ± 4 mm Hg, 1.3-fold baseline; P < 0.05). A similar pattern was observed for the
maximal rate of left ventricular pressure decline
(
dP/dtmax; not shown).


|



1,
P > 0.05, 10 versus 2 min) (Fig. 3B). The effect of
O
-acetyl-L-arginine (87% of
baseline; n = 4, not shown), and to a lesser extent,
aminoguanidine (80% of baseline) prevented O

|



-acetyl-L-arginine were likewise
without effect (n = 4, not shown for the sake of
clarity). The coronary relaxant was neither
H2O2 nor peroxynitrite,
because catalase was present during the experiment and neither urate
nor methionine prevented the decrease in coronary perfusion pressure.
We also tested whether urate itself, which is stoichiometrically formed by the hypoxanthine/xanthine oxidase reaction, was responsible for the
decline in coronary perfusion pressure, but this was not the case
(concentration, 400 µM; n = 4, not shown). However,
oxygen radicals have been shown to stimulate cardiac norepinephrine
release, and the release was inhibitable by different radical
scavengers (Chahine et al., 1991
-receptor stimulation with
phenylephrine (Fig. 4C).
|
In Vitro O





1 (control, Fig.
5). As expected, no signal above background was detectable in the
perfusion medium in the presence of SOD. Interestingly, however,
L-arginine, D-arginine, and
L-NNA were equally effective scavengers,
suggesting that these compounds are, indeed, capable of scavenging
O
|
|

-acetyl-L-arginine, ~51% of
control (i.e., ~49% inhibition) for D-arginine
and derivatives of L-arginine (L-NAME, L-NNA,
L-NMMA), and 72 ± 7% of control (i.e.,
28% inhibition) for aminoguanidine. Glycine had no effect on the rate
of cytochrome c reduction at concentrations up to 10 mM.
Thus, the results again indicated that L-arginine
exhibits O
-amino/carboxyl moieties
(N-
-acetyl-L-arginine and
aminoguanidine, but not glycine, exhibited scavenging activity).
O



1.
|
|
| |
Discussion |
|---|
|
|
|---|
The objective of the present study was to investigate whether L-arginine exerts protective effects against oxygen-mediated myocardial injury by directly scavenging radicals. This was studied in isolated perfused hearts in combination with in vitro quantification of free radicals using established methods. We have made three new observations: 1) L-arginine clearly prevents oxygen radical-induced cardiac contractile dysfunction by diminishing the generation of oxygen radicals; 2) the radical scavenging activity of L-arginine is concentration-dependent; and 3) the scavenging activity can be demonstrated using EPR spectroscopy. These data suggest that a free radical-scavenging action cannot be excluded from explanations of the protective effect of L-arginine.
We chose the crystalloid perfusion method to "isolate" the
scavenging activity of the test compounds from that of other potential scavengers (proteins, thiols), which might be present in more complex
media. Furthermore, for determination of oxygen radical flux rates it
was important to avoid any interference from plasma components or blood
cells that might obscure the relation to the observed cardiac
dysfunction. Exposure of hearts to oxygen radicals generated by
electrolysis, or to O
dP/dtmax,
which are sensitive indices of left ventricular contractility. Previous
authors have mostly used the left ventricular developed pressure as
index of myocardial function (Jackson et al., 1986
; Lecour et al.,
1998
). None of the two radical sources we used was arrhythmogenic, in
agreement with previous observations in normoxic perfused hearts
(Svendsen and Bjerrum, 1992
). Perfusion of hearts in the presence of
L-arginine prevented the decline in left ventricular
contractility caused by electrolysis of the buffer or the addition of
hypoxanthine/xanthine oxidase, presumably due to
scavenging of O
; Brunner et al., 1997
).
The protective effect of L-arginine against oxygen
radical-induced myocardial injury is usually attributed to stimulated
NOS activity resulting from increased substrate availability. However, the results of this study clearly indicate that the protective effect
of L-arginine is related to its potential to scavenge
oxygen radicals. This conclusion is based on the following evidence. First, NOS inhibitors and other derivatives of L-arginine
were similarly effective in protecting hearts and in scavenging
radicals (see Figs. 2, 5, and 6). Second, D-arginine, which
does not serve as NOS substrate, mimicked L-arginine in
protecting the hearts and scavenging radicals. Third, the amino acid
glycine neither prevented the O


).
The apparent rate constant for the reaction of L-arginine
with O
1 [i.e., of
similar magnitude as the reaction of O
-tocopherol (4.5 × 103 M s
1), but
two orders of magnitude smaller than the reaction of O
1) (Gotoh and Niki, 1992
)]. These constants
are given for comparison, but they allow as yet no conclusion as to the
antioxidant potential of L-arginine, because we presently
know neither the underlying mechanism for the reaction between
O
). It is for this reason that D-arginine is no useful
control in in vivo experiments to show that L-arginine
effects are due to stimulation of NOS activity. Despite this, it is
conceivable that L-arginine is taken up by cells and exerts
its action intracellularly, whereas D-arginine has an
extracellular protective effect. Irrespective of this, the present
results clearly strengthen the view that L-arginine may act
as radical scavenger in biological systems (Wascher et al., 1997
). This
action may at least partly account for the antiatherosclerotic effects
of L-arginine (Böger et al., 1995
; Clarkson et al.,
1996
) and provide an additional rationale for its use as a dietary
supplement in different diseases (Velianou et al., 1999
).
We compared the radical scavenging potential of L-arginine
with that of glycine and aminoguanidine, because glycine represents a
simple
-amino carboxylic acid, whereas the aminoguanidine is expected to mimic the guanidinium group of L-arginine. The
findings with glycine were consistent in the hypoxanthine/xanthine
oxidase model where it was neither protective nor a radical scavenger. Glycine is an efficient scavenger of hypochlorous acid, which is formed
during electrolysis from
H2O2 and chlorine (+ electrons) (Jackson et al., 1986
). Therefore, the partial protection in
the electrolysis model was probably due to scavenging of hypochlorous acid, without significantly affecting CLA-based chemiluminescence (Fig.
5), which is rather specific for O
-amino carboxylic acid
structure. This finding was further corroborated using
N-
-acetyl-L-arginine which was
cardioprotective and similarly potent in scavenging O
-amino group (Wallner et al., 2001
). These authors used
copper or 2,2'-azo-bis(2-amidinopropane) hydrochloride to generate free
radicals, and the inhibition of serum lipoprotein oxidation as a
measure of antioxidant effects. Although this latter method has been
widely used, it is rather indirect and less specific than our approach
in which the antioxidant effect of the test compound can be attributed
to a chemically defined radical (O
Exposure of hearts to electrolyzed buffer resulted in an increase in
coronary perfusion pressure, which is in agreement with previous
reports (Jackson et al., 1986
; Lecour et al., 1998
). This is probably
largely due to oxidative consumption of NO released from the vascular
endothelium. In addition, hypochlorous acid, which may be formed during
electrolysis, exerts coronary constrictor effects (Eley et al., 1991
).
On the other hand, exposure to hypoxanthine/xanthine oxidase resulted
in a considerable decrease of perfusion pressure, indicating
substantial reduction in coronary resistance. Because of the presence
of catalase, H2O2 was
probably not involved. This also excluded the possibility that the
relaxation was caused by increased availability of NO after activation
of NOS by H2O2 (Zembowicz et al., 1993
). Urate, which is stoichiometrically formed by the hypoxanthine/xanthine oxidase reaction, was also excluded because it
had no vascular or myocardial effects. Finally, peroxynitrite was
excluded by the lack of effect of the scavengers urate and methionine.
Irreparable vascular damage was also unlikely to be involved because
exogenous phenylephrine elevated coronary perfusion pressure in
concentration-dependent fashion far above the baseline level (Fig. 4C).
However, the combined blockade of
- and
-adrenergic receptors
largely prevented the reduction in perfusion pressure, indicating that
endogenous norepinephrine caused the relaxation (Fig. 4B). This is
in line with the stimulated cardiac norepinephrine release in response
to free radical exposure (Chahine et al., 1991
) and the sustained
coronary dilator effect of norepinephrine, which follows a brief and
transient constricting phase (unpublished observations).
In conclusion, besides possibly increasing the formation of NO, L-arginine has substantial concentration-dependent antioxidant properties, suggesting that its well known vascular and myocardial protective effects occur partly through this mechanism. Future experiments will show to what extent this mechanism plays a role in pathophysiological situations in vivo, where other competing antioxidant systems may be present.
| |
Footnotes |
|---|
Received August 21, 2001; Accepted January 16, 2002
This work was supported by Grants 12934, 13759 (to F.B.), 13784 and 13013 (to B.M.) from the Fonds zur Förderung der Wissenschaftlichen Forschung in Austria.
Address correspondence to: Dr. Friedrich Brunner, Institut für Pharmakologie und Toxikologie, Karl-Franzens-Universität Graz, Universitätsplatz 2, A-8010 Graz, Austria. E-mail: friedrich.brunner{at}kfunigraz.ac.at
| |
Abbreviations |
|---|
NO, nitric oxide;
NOS, nitric oxide synthase;
L-NAME, NG-nitro-L-arginine methyl
ester;
EPR, electron paramagnetic resonance;
TEMPONE-H, 1-hydroxy-2,2,6,6-tetramethyl-4-oxo-piperidine;
CLA, Cypridina luciferin analog;
L-NMMA, NG-monomethyl-L-arginine;
SOD, superoxide dismutase;
DTPA, diethylenetriaminepentaacetic acid;
L-NNA, NG-nitro-L-arginine;
O
| |
References |
|---|
|
|
|---|
Restoration of endothelium-dependent responses by L-arginine.
Circ Res
70:
465-476This article has been cited by other articles:
![]() |
K. J. Greenlee, Z. Werb, and F. Kheradmand Matrix Metalloproteinases in Lung: Multiple, Multifarious, and Multifaceted Physiol Rev, January 1, 2007; 87(1): 69 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Pozo-Navas, H. Stessel, G. Wolkart, and F. Brunner Role of Myocardial Nitric Oxide in Diabetic Ischemia-Reperfusion Dysfunction: Studies in Mice with Myocyte-Specific Overexpression of Endothelial Nitric-Oxide Synthase J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 729 - 738. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Chohan, R. B. Singh, N. S. Dhalla, and T. Netticadan L-Arginine administration recovers sarcoplasmic reticulum function in ischemic reperfused hearts by preventing calpain activation Cardiovasc Res, January 1, 2006; 69(1): 152 - 163. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Saxena and P. K. Chakraborti Identification of Regions Involved in Enzymatic Stability of Peptide Deformylase of Mycobacterium tuberculosis J. Bacteriol., December 1, 2005; 187(23): 8216 - 8220. [Abstract] [Full Text] [PDF] |